Literature DB >> 18640077

Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies.

Igor F Tsigelny1, Yuriy Sharikov, Mark A Miller, Eliezer Masliah.   

Abstract

Misfolding and oligomerization of unstructured proteins is involved in the pathogenesis of Parkinson's disease (PD), Alzheimer's disease, Huntington's disease, and other neurodegenerative disorders. Elucidation of possible conformations of these proteins and their interactions with the membrane is necessary to understand the molecular mechanisms of neurodegeneration. We developed a strategy that makes it possible to elucidate the molecular mechanisms of alpha-synuclein aggregation-a key molecular event in the pathogenesis of PD. This strategy can be also useful for the study of other unstructured proteins involved in neurodegeneration. The results of these theoretical studies have been confirmed with biochemical and electrophysiological studies. Our studies provide insights into the molecular mechanism for PD initiation and progression, and provide a useful paradigm for identifying possible therapeutic interventions through computational modeling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640077      PMCID: PMC2627560          DOI: 10.1016/j.nano.2008.05.005

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  24 in total

1.  A database and tools for 3-D protein structure comparison and alignment using the Combinatorial Extension (CE) algorithm.

Authors:  I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  The pi-helix translates structure into function.

Authors:  T M Weaver
Journal:  Protein Sci       Date:  2000-01       Impact factor: 6.725

3.  Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations.

Authors:  V N Uversky; H J Lee; J Li; A L Fink; S J Lee
Journal:  J Biol Chem       Date:  2001-11-23       Impact factor: 5.157

4.  Finding needles in haystacks: Reranking DOT results by using shape complementarity, cluster analysis, and biological information.

Authors:  Dennis S Law; Lynn F Ten Eyck; Omer Katzenelson; Igor Tsigelny; Victoria A Roberts; Mike E Pique; Julie C Mitchell
Journal:  Proteins       Date:  2003-07-01

Review 5.  A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.

Authors:  Vladimir N Uversky
Journal:  J Biomol Struct Dyn       Date:  2003-10

6.  Mapping of a gene for Parkinson's disease to chromosome 4q21-q23.

Authors:  M H Polymeropoulos; J J Higgins; L I Golbe; W G Johnson; S E Ide; G Di Iorio; G Sanges; E S Stenroos; L T Pho; A A Schaffer; A M Lazzarini; R L Nussbaum; R C Duvoisin
Journal:  Science       Date:  1996-11-15       Impact factor: 47.728

7.  Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes.

Authors:  W S Davidson; A Jonas; D F Clayton; J M George
Journal:  J Biol Chem       Date:  1998-04-17       Impact factor: 5.157

Review 8.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

9.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.

Authors:  P Ibáñez; A-M Bonnet; B Débarges; E Lohmann; F Tison; P Pollak; Y Agid; A Dürr; A Brice
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

10.  Amyloids of shuffled prion domains that form prions have a parallel in-register beta-sheet structure.

Authors:  Frank Shewmaker; Eric D Ross; Robert Tycko; Reed B Wickner
Journal:  Biochemistry       Date:  2008-03-07       Impact factor: 3.162

View more
  24 in total

1.  Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

Authors:  Omar El-Agnaf; Cassia Overk; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Nishant Vaikath; Nour Majbour; Seung-Jae Lee; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2017-05-02       Impact factor: 5.996

2.  Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  Neurotox Res       Date:  2011-07-07       Impact factor: 3.911

3.  α-Synuclein (αSyn) Preformed Fibrils Induce Endogenous αSyn Aggregation, Compromise Synaptic Activity and Enhance Synapse Loss in Cultured Excitatory Hippocampal Neurons.

Authors:  Qihui Wu; Hajime Takano; Dawn M Riddle; John Q Trojanowski; Douglas A Coulter; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2019-04-29       Impact factor: 6.167

4.  Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders.

Authors:  Stefano G Daniele; Dawn Béraud; Connor Davenport; Kui Cheng; Hang Yin; Kathleen A Maguire-Zeiss
Journal:  Sci Signal       Date:  2015-05-12       Impact factor: 8.192

Review 5.  α-Synuclein Misfolding Versus Aggregation Relevance to Parkinson's Disease: Critical Assessment and Modeling.

Authors:  Ruben Berrocal; Velmarini Vasquez; Sambasiva Rao Krs; Bharathi S Gadad; K S Rao
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

Review 6.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 7.  Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease.

Authors:  Cassia R Overk; Eliezer Masliah
Journal:  Biochem Pharmacol       Date:  2014-01-21       Impact factor: 5.858

8.  Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity.

Authors:  Diana L Price; Edward Rockenstein; Kiren Ubhi; Van Phung; Natalie MacLean-Lewis; David Askay; Anna Cartier; Brian Spencer; Christina Patrick; Paula Desplats; Mark H Ellisman; Eliezer Masliah
Journal:  PLoS One       Date:  2010-11-16       Impact factor: 3.240

9.  A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Authors:  Wolfgang Wrasidlo; Igor F Tsigelny; Diana L Price; Garima Dutta; Edward Rockenstein; Thomas C Schwarz; Karin Ledolter; Douglas Bonhaus; Amy Paulino; Simona Eleuteri; Åge A Skjevik; Valentina L Kouznetsova; Brian Spencer; Paula Desplats; Tania Gonzalez-Ruelas; Margarita Trejo-Morales; Cassia R Overk; Stefan Winter; Chunni Zhu; Marie-Francoise Chesselet; Dieter Meier; Herbert Moessler; Robert Konrat; Eliezer Masliah
Journal:  Brain       Date:  2016-09-27       Impact factor: 13.501

Review 10.  Function and dysfunction of α-synuclein: probing conformational changes and aggregation by single molecule fluorescence.

Authors:  Adam J Trexler; Elizabeth Rhoades
Journal:  Mol Neurobiol       Date:  2012-09-16       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.